Physician profile
Matthew C Johnson
NPI 1912133638
$2,168.04
in general payments reported to CMS, 2019-2025
15 companies · $143 in 2025
The $143 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $202 · 2020: $31.62 · 2021: $1,134 · 2022: $218 · 2023: $220 · 2024: $219 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $582.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $581.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Omeros Corporation | $1,036.97 | 2019-2021 | |
| Biotissue Holdings INC. | $275.97 | 2019-2023 | |
| Alcon Vision LLC | $232.42 | 2019-2025 | Rocklatan, Clareon, Hydrus Microstent |
| Harrow Eye, LLC | $163.08 | 2024 | Iheezo |
| Carl Zeiss Meditec USA, INC. | $120.44 | 2021 | |
| Novartis Pharmaceuticals Corporation | $77.99 | 2019-2022 | |
| Sight Sciences, INC. | $48.68 | 2025 | Omni Surgical System, Sion Surgical Instrument |
| Sun Pharmaceutical Industries INC. | $48.14 | 2019-2025 | |
| Merz North America, INC. | $31.21 | 2019 | |
| Apellis Pharmaceuticals, INC. | $30.88 | 2024 | Syfovre |
| Thea Pharma INC. | $24.49 | 2022 | |
| Bausch & Lomb Americas INC. | $23.88 | 2023 | Vyzulta |
| Aerie Pharmaceuticals, INC. | $21.92 | 2019 | |
| Kala Pharmaceuticals, INC. | $17.88 | 2019 | |
| Nestle Healthcare Nutrition INC. | $14.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.